Oliver Lagore Vanvalin Investment Group Avidity Biosciences, Inc. Transaction History
Oliver Lagore Vanvalin Investment Group
- $370 Million
- Q4 2024
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 663 shares of RNA stock, worth $19,432. This represents 0.01% of its overall portfolio holdings.
Number of Shares
663
Previous 1,754
62.2%
Holding current value
$19,432
Previous $80,000
76.25%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
244Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$335 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$332 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$284 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$271 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$256 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.53B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...